Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle

Gene Therapy

Volumn 9, Issue 21, 2002, Pages 1429-1437

  Martinenghi, S ^a,b   De Angelis, G Cusella ^c   Biressi, S ^a   Amadio, S ^b   Bifari, F ^a   Roncarolo, M G ^a   Bordignon, C ^a   Falqui, L ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Diabetes; Electrotransfer; Gene transfer; Plasmid; Skeletal muscle

Indexed keywords

COMPLEMENTARY DNA; FURIN; GLUCOSE; HUMAN INSULIN; PLASMID DNA; PROINSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DATA ANALYSIS; DIET RESTRICTION; DISEASE SEVERITY; FEEDING; GENE THERAPY; GENE TRANSFER; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; IMMUNOCOMPETENCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SKELETAL MUSCLE; STREPTOZOCIN DIABETES; SURVIVAL TIME; TISSUE ENGINEERING;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DNA; ELECTROPORATION; GENE THERAPY; INJECTIONS, INTRAMUSCULAR; INSULIN; MALE; MICE; MICE, SCID; MUSCLE, SKELETAL;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0036845732     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301804     Document Type: Article

References (48)

1. Diabetes Control and Complication Trial Research Group (DCCT) The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Gautier JF et al. Are the implications of the Diabetes Control and Complications Trial (DCCT) feasible in daily clinical practice? Diabetes Metab 1996; 22: 415-419.
3. Diabetes Control and Complication Trial Research Group (DCCT) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286.
4. Hanaire-Broutin H et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin Lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 2000; 23: 1232-1235.
5. Scavini M et al. Catheter survival during long-term insulin therapy with an implanted programmable pump. The Implantable Insulin Pump Trial Study group. Diabetes Care 1997; 20: 610-613.
6. Thompson JS, Duckworth WC, Saudek CD, Giobbie-Hurder A. Surgical experience with implatable insulin pumps. Department of Veterans Affairs Implantable Insulin Pump Study Group. Am J Surg 1998; 176: 622-626.
7. Selam JL. External and implantable insulin pumps: current place in the treatment of diabetes. Exp Clin Endocrinol Diabetes 2001; 109: S333-S340.
8. Gruessner AC, Sutherland DE. Analysis of pancreas transplant outcomes for United States cases reported to the United Network for Organ Sharing (UNOS) and non-US cases reported to the International Pancreas Transplant Registry (IPTR). Clin Transpl 1999; 51-69.
9. Martinenghi S et al. Cancer arising after pancreas and/or kidney transplantation in a series of 99 diabetic patients. Diabetes Care 1997; 20: 272-275.
10. Lumbreras C et al. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995; 20: 514-520.
11. Smets YF et al. Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transpl 1997; 12: 764-771.
12. Secchi A et al. Islet transplantation in IDDM patients. Diabetologia 1997; 40: 225-231.
13. Shapiro AM et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
14. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type I diabetes - the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
15. Karvonen M et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23: 1516-1526.
16. Song S et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14394-14398.
17. Haase G et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. J Neurol Sci 1998; 160: S97-S105.
18. Kay MA et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genetics 2000; 24: 257-261.
19. Tripathy SK et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93: 10876-10880.
20. Kon OL et al. Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus. J Gene Med 1999; 1: 186-194.
21. Athanasopoulos T et al. Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice. Hum Mol Genet 2000; 9: 2545-2551.
22. Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
23. Wolff JA et al. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991; 11: 474-485.
24. Wolff JA et al. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 1992; 103: 1249-1259.
25. Aihara H, Miyazaki JI. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
26. Mir LM et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-4267.
27. Draghia-Akli R et al. Myogenic expression of an injectable protease-resistant growth hormone releasing hormone augments long-term growth in pigs. Nat Biotechnol 1999; 17: 1179-1183.
28. Maruyama H et al. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 2000; 11: 429-437.
29. Rizzuto G et al. Gene electrotransfer results in a high level transduction of rat skeletal muscle and correct anemia of renal failure. Hum Gene Ther 2000; 11: 1891-1900.
30. Groskreutz DJ, Sliwkowski MX, Gorman CM. Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem 1994; 269: 6241-6245.
31. Falqui L et al. Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Hum Gene Ther 1999; 10: 1753-1760.
32. Dong H et al. Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes 2002; 51: 130-138.
33. Lee HC et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408: 483-488.
34. Yin D, Tang J-G. Gene therapy for streptozotocin-induced diabetic mice by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo. FEBS Lett 2001; 495: 16-20.
35. Shifrin AL et al. Adenoviral vector-mediated insulin gene transfer in the mouse pancreas corrects streptozotocin-induced hyperglycemia. Gene Therapy 2001; 8: 1480-1489.
36. Cheung AT et al. Glucose-dependent insulin release from genetically engineered K cells. Science 2000; 290: 1959-1962.
37. Simonson GD, Grokreutz DJ, Gorman CM, Macdonald MJ. Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures. Hum Gene Ther 1996; 7: 71-78.
38. Arcelloni C et al. Processing and release of human proinsulin-cleavage products into culture media by different engineered non-endocrine cells: a specific assessment by capillary electrophoresis. J Endocrinol 2000; 166: 437-445.
39. McMahon JM et al. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase -increased expression with reduced muscle damage. Gene Ther 2001; 8: 1264-1270.
40. Hartikka J et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4: 407-415.
41. Skarli M et al. Myosin regulatory elements as vectors for gene transfer by intramuscular injection. Gene Therapy 1998; 5: 514-520.
42. Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 1999; 17: 241-245.
43. Abai AM, Hobart PM, Barnhart KM. Insulin delivery with plasmid DNA. Hum Gene Ther 1999; 10: 2637-2649.
44. Stewart T, Taylor NA, Docherty K, Bailey CJ. Insulin delivery by somatic cell gene therapy. J Mol Endocrinol 1993; 11: 335-341.
45. Diabetes Control and Complication Trial Research Group (DCCT) Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the diabetes control and complication trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
46. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
47. Manthorpe M et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 1993; 4: 419-431.
48. Ferrari G et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530.